Epithelial ovarian cancer remains the most lethal gynaecological malignancy in developed countries despite efforts to improve oncological outcomes by building on the established front-line chemotherapy backbone of carboplatin and paclitaxel administered every 3 weeks. 1 Investigators have examined platinumbased triplet regimens, and sequential doublets without improvements in progression-free survival. 2 It was not until the incorporation of the anti-angiogenic antibody bevacizumab that considerable improvements in progression-free survival were made. 3, 4 Recently, substantial gains were realised with the incorporation of maintenance poly(ADP-ribose) polymerase inhibitors (PARPi) in biomarker selected populations (patients with BRCA mutation and homologous recombination deficient). SOLO-1 randomly assigned patients with a BRCA mutation and newly diagnosed advanced stage ovarian cancer to olaparib or placebo after a complete or partial response to platinumbased chemotherapy. 5 Olaparib maintenance resulted in a 3-year improvement in median progression-free survival over placebo (hazard ratio [HR] 0·30; p<0·001) and the median progression-free survival had not yet been reached in the olaparib group (vs 13·8 months in the placebo group). The magnitude of benefit, in terms of HR, identified in the SOLO-1 trial has since been approached in three studies examining maintenance PARPi in the front-line setting. PRIMA/GOG-3012, PAOLA-1, and VELIA/GOG-3005, all presented at the 2019 European Society for Medical Oncology meeting, showed a significant reduction in the risk of progression in biomarker selected cohorts, calling into question the relevance of cytotoxic drug dosing as part of primary therapy.
Before the biomarker driven drug discovery that resulted in PARPi approval, investigators studied the potential benefits of weekly paclitaxel drug delivery. 6, 7 In JGOG 3016, carboplatin and paclitaxel every 3 weeks versus carboplatin every 3 weeks plus weekly paclitaxel was assessed. This trial showed both a significant improvement in progression-free survival and overall survival. 8 Subsequently, Chan and colleagues (GOG-0262) looked to establish whether dose-dense weekly paclitaxel and carboplatin would prolong progression-free survival in patients receiving and those not receiving bevacizumab. 9 In the intention-to-treat population, no improvement in progression-free survival was identified. Conversely in the non-bevacizumab cohort (16% of patients), a 3·9-month improvement in progression-free survival was seen in the dose-dense paclitaxel group.
In The Lancet, Andrew Clamp and colleagues report the results of the ICON8 study, 10 which investigated the potential therapeutic benefit of dose-dense paclitaxel in conjunction with carboplatin in 1566 women with stage 1C-IV epithelial ovarian cancer. The study compared 3-weekly carboplatin plus 3-weekly paclitaxel (group 1, n=522) with two separate study groups: 3-weekly carboplatin plus weekly paclitaxel (group 2, n=523) and weekly carboplatin plus weekly paclitaxel (group 3, n=521). The authors reported no significant improvement in progression-free survival in either weekly regimen compared with the control group despite successfully achieving paclitaxel dose intensi fication. The restricted mean survival time was 24·5 months in group 1 (97·5% CI 23·0-26·0), 24·9 months in group 2 (24·0-25·9), and 25·4 months in group 3 (23·9-26·9; group 1 vs group 2 log-rank p=0·35; group 1 vs group 3 log-rank p=0·51). Estimated 2-year overall survival was 80% (95% CI 76-83) in group 1, 82% (78-85) in group 2, and 78% (74-81) in group 3. Furthermore, the weekly regimens were associated with an increased frequency of anaemia and neutropenia. On the basis of the study findings, the authors concluded that 3-weekly carboplatin and paclitaxel should remain the preferred chemotherapy regimen for the front-line treatment of ovarian carcinoma.
The results of ICON8 are informative, re-establishing 3-weekly delivery as standard care, although questions remain. The discrepant adverse event frequencies reported in JGOG 3016, GOG-0262, and ICON8 might reflect the relevance of pharmacogenomics in drug delivery and efficacy, or alternatively reflect differences in drug dosing between trials. The JGOG 3016 study reported a 53% discontinuation rate in the weekly paclitaxel study group, greater than that reported on ICON8 or GOG-0262, although both carboplatin and paclitaxel dosing were higher than that in the comparator trials. The relevance of haematological toxicity on outcomes remains unclear, although investigators have suggested that the presence of chemotherapy-induced neutropenia might be associated with improved outcomes. 11 Additionally, polymorphisms in paclitaxel-metabolising enzymes, transporters, and targets might influence toxicity and response, with ethnicity-specific differences. 12 In the context of the ethnic diversity between the above-mentioned trials, weekly paclitaxel might have a beneficial effect on survival in a particular patient subset. Further limitations of the ICON8 trial include the incorporation of early stage patients at high risk (20% stage 1C-II), which might have diluted the treatment effect, as well as a greater frequency of patients on neoadjuvant chemotherapy than initially anticipated, affecting the power to detect a meaningful difference among study groups.
Furthermore, incorporation of bevacizumab could abrogate any benefits seen with weekly paclitaxel administration. Although JGOG 3016 did not incorporate bevacizumab, the potential results of the ICON8B trial (NCT01654146) might support the findings of GOG-0262. Ultimately, the 3-weekly regimen appears to be equally efficacious, less toxic, and easier to administer. However, some argue that we are beyond the era of cytotoxic drugs, as novel combinatorial approaches using PARPi, immune checkpoint inhibitors, and anti-angiogenics are currently being examined.
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